Sunday, February 5, 2023 | Back issues
Courthouse News Service Courthouse News Service

Shareholder Class Action

A shareholder class action accusers directors of “a massive fraud that has left Akorn — a once-vibrant multibillion-dollar pharmaceutical company — in ruins,” in federal court.

CHICAGO — A shareholder class action accuses directors of “a massive fraud that has left Akorn — a once-vibrant multibillion-dollar pharmaceutical company — in ruins,” in federal court.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.

Loading
Loading...